Analysts See $-0.17 EPS for AC Immune Ltd (ACIU); Invuity (IVTY) Shorts Increased By 3.92%

May 30, 2017 - By Migdalia James

Analysts expect AC Immune Ltd (NASDAQ:ACIU) to report $-0.17 EPS on June, 16. It closed at $8.91 lastly. It is down 0.00% since May 30, 2016 and is . It has underperformed by 16.70% the S&P500.

Invuity Incorporated (NASDAQ:IVTY) had an increase of 3.92% in short interest. IVTY’s SI was 525,300 shares in May as released by FINRA. Its up 3.92% from 505,500 shares previously. With 90,000 avg volume, 6 days are for Invuity Incorporated (NASDAQ:IVTY)’s short sellers to cover IVTY’s short positions. The SI to Invuity Incorporated’s float is 4.64%. The stock decreased 2.60% or $0.2 on May 26, reaching $7.5. About shares traded. Invuity, Inc. (NASDAQ:IVTY) has risen 50.92% since May 30, 2016 and is uptrending. It has outperformed by 34.22% the S&P500.

Among 2 analysts covering Invuity Inc (NASDAQ:IVTY), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Invuity Inc had 2 analyst reports since August 29, 2016 according to SRatingsIntel. Craig Hallum initiated it with “Buy” rating and $25 target in Monday, August 29 report. On Monday, September 19 the stock rating was initiated by Lake Street with “Buy”.

AC Immune Ltd is a Switzerland-based firm engaged in the medical biotechnology sector. The company has market cap of $505.02 million. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms. It currently has negative earnings.